Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapy
Eflapegrastim-xnst, administered same day as TC chemotherapy was effective and well tolerated evidenced by short time to neutrophil recovery and low incidence of FN, with an adverse event profile similar to that of next-day dosing.
Authors
- Howard Franklin
- Jeffrey Vacirca
- Lee S. Schwartzberg (ORCID: https://orcid.org/0000-0002-7433-3428)
- Keith A. Crist
- Shanta Chawla
- Manuel Modiano
Institutions
- Lake Forest College (US)
- Renown Health (US)
- Arizona Research Center (US)
- Spectrum Pharmaceuticals (United States) (US)
- Georgia Cancer Specialists (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-13
- DOI
- https://doi.org/10.1093/oncolo/oyaf415
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00